William D Tutrone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William D Tutrone has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey M Weinberg
7 shared publicationsRitu Saini
4 shared publicationsSelin Caglar
3 shared publicationsJorge Crespo
2 shared publicationsBruce E Strober
1 shared publicationDick Clarke
1 shared publication
Latest Publications
- 1 December 2007
- Vol. 6 (12) , 1214-9
Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of skin and subcutaneous tissue. The current accepted theory is that PG is an immunologic-based phenomenon. Several therapies have been used to control this disease, including corticosteroids, antibiotics, immunotherapy, dapsone, and hyperbaric oxygen therapy. This article will review the application of hyperbaric oxygen (HBO) therapy in patients with PG. Information for this manuscript was derived from multiple searches of MEDLINE and the National Baromedical Service literature collection. HBO therapy has been shown to effectively treat PG ulcers and reduce pain associated with PG in several case studies. Evidence from the studies cited herein help to establish a foundation for further research to investigate the role of HBO therapy as an adjuvant therapy in the treatment of PG.
- 1 December 2007
- Vol. 6 (12) , 1214-9
Pyoderma gangrenosum: dermatologic application of hyperbaric oxygen therapy.
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of skin and subcutaneous tissue. The current accepted theory is that PG is an immunologic-based phenomenon. Several therapies have been used to control this disease, including corticosteroids, antibiotics, immunotherapy, dapsone, and hyperbaric oxygen therapy. This article will review the application of hyperbaric oxygen (HBO) therapy in patients with PG. Information for this manuscript was derived from multiple searches of MEDLINE and the National Baromedical Service literature collection. HBO therapy has been shown to effectively treat PG ulcers and reduce pain associated with PG in several case studies. Evidence from the studies cited herein help to establish a foundation for further research to investigate the role of HBO therapy as an adjuvant therapy in the treatment of PG.
- 1 April 2006
- Published by Taylor & Francis in Expert Review of Dermatology
- Vol. 1 (2) , 207-216
Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept
- 1 April 2006
- Published by Taylor & Francis in Expert Review of Dermatology
- Vol. 1 (2) , 207-216
Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept
- 1 November 2003
- Vol. 72 (5) , 405-6
The Köbner phenomenon and psoriatic arthritis.
Psoriatic arthritis (PsA) affects a large percentage of patients with psoriasis. Similar to the cutaneous disease of psoriasis, PsA displays an isomorphic response (ie, the propensity to develop at traumatized sites). In some patients, traumatized joints that subsequently develop PsA are the initial manifestation of psoriasis, preceding the skin disease by months to years. Dermatologists should screen patients with psoriasis for accompanying PsA and consider recently traumatized joints that remain arthritic to be a component of this disease.
- 1 November 2003
- Vol. 72 (5) , 405-6
The Köbner phenomenon and psoriatic arthritis.
Psoriatic arthritis (PsA) affects a large percentage of patients with psoriasis. Similar to the cutaneous disease of psoriasis, PsA displays an isomorphic response (ie, the propensity to develop at traumatized sites). In some patients, traumatized joints that subsequently develop PsA are the initial manifestation of psoriasis, preceding the skin disease by months to years. Dermatologists should screen patients with psoriasis for accompanying PsA and consider recently traumatized joints that remain arthritic to be a component of this disease.
- 1 May 2003
- Vol. 71 (5) , 365-70
Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod.
Actinic keratoses (AKs) are evolving, malignant cutaneous neoplasms. AKs can be treated with physical or destructive methods and with topical therapies. This article is the first in a 2-part series that will review current topical therapeutic options for AKs. Several topical treatment options offer some significant benefit for the alleviation of these lesions. Therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine, and retinoids. The first part of this review will focus on topical 5-fluorouracil and imiquimod.
- 1 May 2003
- Vol. 71 (5) , 365-70
Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod.
Actinic keratoses (AKs) are evolving, malignant cutaneous neoplasms. AKs can be treated with physical or destructive methods and with topical therapies. This article is the first in a 2-part series that will review current topical therapeutic options for AKs. Several topical treatment options offer some significant benefit for the alleviation of these lesions. Therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine, and retinoids. The first part of this review will focus on topical 5-fluorouracil and imiquimod.
- 1 May 2003
- Vol. 71 (5) , 373-9
Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids.
Actinic keratoses (AKs) are evolving, malignant cutaneous neoplasms. AKs can be treated with physical or destructive methods and by topical therapies. This article is the second in a 2-part series of current topical therapeutic options for AKs and discusses topical diclofenac, colchicine, and retinoids. The first part focused on topical 5-fluorouracil and imiquimod.
- 1 May 2003
- Vol. 71 (5) , 373-9
Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids.
Actinic keratoses (AKs) are evolving, malignant cutaneous neoplasms. AKs can be treated with physical or destructive methods and by topical therapies. This article is the second in a 2-part series of current topical therapeutic options for AKs and discusses topical diclofenac, colchicine, and retinoids. The first part focused on topical 5-fluorouracil and imiquimod.
- 1 January 2003
- Vol. 71 (1) , 41-5
Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
During the past several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept.
- 1 January 2003
- Vol. 71 (1) , 41-5
Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.
During the past several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept.
- 1 December 2002
- Vol. 1 (3) , 303-10
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
- 1 December 2002
- Vol. 1 (3) , 303-10
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Over the last several years, a new generation of therapies for psoriasis has been in development. These biologic therapies target the activity of T lymphocytes and cytokines responsible for the inflammatory nature of this disease. In this review, we present an update on the progress of the four biologic agents in the forefront: infliximab, etanercept, efalizumab, and alefacept. The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data.
- 1 January 2002
- Vol. 69 (1) , 27-33
Cutaneous anthrax: a concise review.
With the growing threat of bioterrorism, it has become important for clinicians to recognize the clinical manifestations of diseases spread in this manner. The aim of this article is to provide readers with a complete and detailed understanding of anthrax, with a specific concentration on the cutaneous manifestations and a concentrated review of the treatment and current information known about Bacillus anthracis.
- 1 January 2002
- Vol. 69 (1) , 27-33
Cutaneous anthrax: a concise review.
With the growing threat of bioterrorism, it has become important for clinicians to recognize the clinical manifestations of diseases spread in this manner. The aim of this article is to provide readers with a complete and detailed understanding of anthrax, with a specific concentration on the cutaneous manifestations and a concentrated review of the treatment and current information known about Bacillus anthracis.